{"id":46680,"date":"2022-07-28T14:01:45","date_gmt":"2022-07-28T12:01:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/"},"modified":"2022-07-28T14:01:45","modified_gmt":"2022-07-28T12:01:45","slug":"crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/","title":{"rendered":"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience<\/a>, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nEffective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development.\n<\/p>\n

\nBuilding on the company\u2019s continued growth, three new roles have been created within the commercial team and will report to Mr. Prosser. Alex Slater, who joined the company last year, has taken on added responsibility for APAC business development as Vice President of Global Business Development; Dr. Jonny McMichael has been appointed to Vice President of Client Experience and Enablement; and Dr. Achim Quandt has joined the company as Executive Director of Product Management.\n<\/p>\n

\n\u201cCrown Bioscience has grown significantly in recent years, consistently exceeding its annual growth target, and in FY21 we were delighted to record bookings growth of over 40%,\u201d said Armin Spura, CEO. \u201cWith these changes announced today and under Michael’s continued leadership, we are confident we are putting in place a commercial team that optimally positions Crown Bioscience for our next phase of growth.\u201d\n<\/p>\n

\nMichael Prosser, CBO, stated: \u201cIt\u2019s an honor to be asked to lead the next stage in Crown Bioscience\u2019s commercial growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation, and setting new industry-leading quality standards, and I\u2019m excited to be working closely with the new team and structure as we strive to continuously improve in all these areas.\u201d\n<\/p>\n

\nThe company added more than four hundred new customers in FY21, and to meet increased customer demand, has accelerated investments in its global footprint, with renovations now complete in APAC laboratories, and notably the formation of a joint venture with sister company MBL in Japan. In Europe and the United States, parallel investments are also planned for site expansions and strategic acquisitions.\n<\/p>\n

\n###\n<\/p>\n

\nAbout Crown Bioscience<\/b>\n<\/p>\n

\nCrown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world\u2019s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https:\/\/www.crownbio.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCrown Bioscience
\n
Louise Stenson
\n
pr@crownbio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent. Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46680","6":"format-standard","7":"category-industry"},"yoast_head":"\nCrown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent. Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T12:01:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220728005025\/en\/1524253\/21\/Mike_Prosser_Headshot.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership\",\"datePublished\":\"2022-07-28T12:01:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/\"},\"wordCount\":465,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005025\\\/en\\\/1524253\\\/21\\\/Mike_Prosser_Headshot.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/\",\"name\":\"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005025\\\/en\\\/1524253\\\/21\\\/Mike_Prosser_Headshot.jpg\",\"datePublished\":\"2022-07-28T12:01:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005025\\\/en\\\/1524253\\\/21\\\/Mike_Prosser_Headshot.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005025\\\/en\\\/1524253\\\/21\\\/Mike_Prosser_Headshot.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/","og_locale":"en_US","og_type":"article","og_title":"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent. Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-28T12:01:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220728005025\/en\/1524253\/21\/Mike_Prosser_Headshot.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership","datePublished":"2022-07-28T12:01:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/"},"wordCount":465,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220728005025\/en\/1524253\/21\/Mike_Prosser_Headshot.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/","url":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/","name":"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220728005025\/en\/1524253\/21\/Mike_Prosser_Headshot.jpg","datePublished":"2022-07-28T12:01:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220728005025\/en\/1524253\/21\/Mike_Prosser_Headshot.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220728005025\/en\/1524253\/21\/Mike_Prosser_Headshot.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/crown-bioscience-appoints-michael-prosser-as-chief-business-officer-and-illustrates-further-investment-in-commercial-leadership\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46680"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46680\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}